Nvidia and Microsoft back AI breakthrough for gene therapies

Nvidia and Microsoft have thrown their weight behind a new AI drive to advance gene therapies. The effort applies large models to genetic design and analysis, with the goal of speeding discovery and cutting costly missteps. Tech teams plan to supply compute and tools, while biotech partners contribute data and lab validation. Supporters say this could sharpen target selection and improve predictions before trials. Skeptics warn about data bias, safety, and oversight. The move adds fuel to a race among cloud and chip providers to win global biopharma workloads as demand for training and inference surges. Researchers and drugmakers see tighter ties with Big Tech as development cycles compress.